Metabolomics study on the therapeutic effect of traditional Chinese medicine Xue-Fu-Zhu-Yu decoction in coronary heart disease based on LC-Q-TOF/MS and GC-MS analysis

The present study aims is to investigate the metabolic mechanism of Xue-Fu-Zhu-Yu decoction (XFZYD) in the treatment of blood-stasis syndrome in Coronary Heart Disease (CHD). To that end, 30 CHD patients with Blood-Stasis Syndrome (BSS) and 20 healthy subjects were enrolled. LC-Q-TOF/MS analysis determined that in comparison between CHD with BSS patients (Group A) and healthy subjects (Group C), 59 significantly differential metabolites in the positive mode and 18 significantly differential metabolites in the negative mode. The metabolite constituents in the plasma of 30 CHD with BSS patients before (group A) and after 30 days of treatment (Group B), and 20 healthy subjects (Group C) were analyzed using LC-Q-TOF/MS and GC-MS. Based on multivariate statistical analysis (PCA, PLS-DA and OPLS-DA), we determined 69 differential metabolites. The levels of hemorheology indexes were significantly down-regulated after treatment. Metabolic pathway attribution analysis showed that lipid metabolism, amino acid metabolism and bile acid metabolism pathways are involved. Our study identifies the metabolic networks of CHD and demonstrates the efficacy of this metabolomics approach to systematically study the therapeutic effect of XFZYC on CHD.     

Creation of an Age-Adjusted,Dual-Energy X-ray Absorptiometry–Derived Trabecular Bone Score Curve for the Lumbar Spine in Non-Hispanic US White Women

The trabecular bone score (TBS, Med-Imaps, Pessac, France) is an index of bone microarchitecture texture extracted from anteroposterior dual-energy X-ray absorptiometry images of the spine. Previous studies have documented the ability of TBS of the spine to differentiate between women with and without fractures among age- and areal bone mineral density (aBMD)-matched controls, as well as to predict future fractures. In this cross-sectional analysis of data collected from 3 geographically dispersed facilities in the United States, we investigated age-related changes in the microarchitecture of lumbar vertebrae as assessed by TBS in a cohort of non-Hispanic US white American women. All subjects were 30 yr of age and older and had an L1–L4aBMDZ-score within ±2 SD of the population mean. Individuals were excluded if they had fractures, were on any osteoporosis treatment, or had any illness that would be expected to impact bone metabolism. All data were extracted from Prodigy dual-energy X-ray absorptiometry devices (GE-Lunar, Madison, WI). Cross-calibrations between the 3 participating centers were performed for TBS and aBMD. aBMD and TBS were evaluated for spine L1–L4 but also for all other possible vertebral combinations. To validate the cohort, a comparison between the aBMD normative data of our cohort and US non-Hispanic white Lunar data provided by the manufacturer was performed. A database of 619 non-Hispanic US white women, ages 30–90 yr, was created. aBMD normative data obtained from this cohort were not statistically different from the non-Hispanic US white Lunar normative data provided by the manufacturer (p = 0.30). This outcome thereby indirectly validates our cohort. TBS values at L1–L4 were weakly inversely correlated with body mass index (r = −0.17) and weight (r = −0.16) and not correlated with height. TBS values for all lumbar vertebral combinations decreased significantly with age. There was a linear decrease of 16.0% (−2.47 T-score) in TBS at L1–L4 between 45 and 90 yr of age (vs. −2.34 for aBMD). Microarchitectural loss rate increased after age 65 by 50% (−0.004 to −0.006). Similar results were obtained for other combinations of lumbar vertebra. TBS, an index of bone microarchitectural texture, decreases with advancing age in non-Hispanic US white women. Little change in TBS is observed between ages 30 and 45. Thereafter, a progressive decrease is observed with advancing age. The changes we observed in these American women are similar to that previously reported for a French population of white women (r² > 0.99). This reference database will facilitate the use of TBS to assess bone microarchitectural deterioration in clinical practice.     

综合护理干预在腰椎疾病患者脊柱融合术后康复中的作用

目的 探讨护理干预在腰椎疾病患者脊柱融合术后康复中的作用。方法 对我院收治的180例行脊柱融合术治疗的腰椎疾病患者实施综合护理干预,比较患者治疗及护理前后的疼痛VAS评分、身体功能JOA评分、直腿抬高角度、腰背伸高度。结果 患者术后6个月疼痛VAS评分、身体功能JOA评分、直腿抬高角度、腰背伸高度较术前均明显改善。结论 对行脊柱融合术治疗的腰椎疾病患者采取综合护理干预有助于手术恢复,能有效缓解疼痛,恢复腰椎运动与神经功能。     

不良孕产史夫妇染色体核型的大样本分析

目的探讨不良孕产史夫妇染色体异常核型检出率及其分布，以及染色体异常核型与不良孕产史的关系，为优生优育及遗传咨询提供理论依据。 方法选取2016年1月1日至2017年12月31日，于济南艾迪康医学检验中心进行染色体核型检测的10 330对(20 660例)不良孕产史育龄夫妇为研究对象。采集每例受试者肘静脉血3 mL，肝素钠抗凝，取0.3 mL进行血细胞培养、标本制备，采用常规G显带技术进行染色体核型分析。对于染色体异常核型检出率、不同类型染色体异常核型占染色体异常核型总例数的比例等计数资料，采用率(%)表示。本研究遵循的程序符合2013年修订的《世界医学协会赫尔辛基宣言》要求。 结果①本组10 330对(20 660例)不良孕产史育龄夫妇中，共计检出染色体异常核型为1 119例(不含染色体多态性)，染色体异常核型检出率为5.42%(1 119/20 660)。其中，常染色体异常者为658例，占染色体异常核型的58.80%(658/1 119)，包括354例染色体平衡易位、205例染色体倒位、83例染色体罗伯逊易位、11例染色体插入、5例染色体重复，分别占染色体异常核型的31.64%、18.32%、7.41%、0.98%、0.45%。染色体倒位者中，以9号染色体倒位居多，偶见于1、4、7、11、12号染色体，并且多合并自然流产。性染色体异常者为440例，占染色体异常核型的39.32%(440/1 119)，包括365例性染色体数目异常(占染色体异常核型的32.62%)。其中，男性多表现为无精子症，以47，XXY染色体异常核型居多(144例)，女性多表现为原发性不孕，以45，X染色体异常核型居多(103例); 61例为性染色体结构异常、14例为性别反转，分别占染色体异常核型的5.45%、1.25%。其他罕见染色体异常核型者为21例，占染色体异常核型的1.88%(21/1 119)，如环状染色体、mar染色体等。②本组10 330对(20 660例)不良孕产史育龄夫妇中，11例为常染色体插入，5例为常染色体重复，54例为性染色体缺失，其主要临床表现为原发性不孕不育、胚胎停止发育、无精子症或重度少精子症。 结论染色体异常核型是导致育龄期夫妇不良孕产史的重要原因之一。对于不良孕产史夫妇，建议进行染色体核型分析和遗传咨询。临床为这类患者进行优生优育指导，可提高出生人口质量。     

下肢静脉曲张术后并发静脉血栓的有效护理干预

目的:分析对下肢静脉曲张术后并发静脉血栓患者的有效护理干预措施。方法:以2019年6月~2019年6月我院收治的42例下肢静脉曲张患者为研究对象,随机分为两组,各21例,对照组常规护理,实验组实施有效护理干预,对比护理效果。结果:对照组下肢静脉曲张术后患者的并发深静脉血栓发生率高于实验组患者,差异具备统计学价值;实验组下肢静脉曲张术后患者的护理满意度高于对照组患者,差异显著且具备统计学意义。结论:下肢静脉曲张术后实施有效护理干预可降低并发静脉血栓发生率,同时提升患者护理满意度,有效改善患者预后,促进患者康复,也有利于维护良好的护患关系,因此应在临床实践中对有效护理干预进行推广与普及。     

Atrial Functional Mitral Regurgitation: JACC Review Topic of the Week

Unlike secondary mitral regurgitation (MR) in the setting of left ventricular (LV) disease, the occurrence of functional MR in atrial fibrillation (AF) and/or heart failure with preserved ejection fraction (HFpEF) has remained largely unspoken. LV size and systolic function are typically normal, whereas isolated mitral annular dilation and inadequate leaflet adaptation are considered mechanistic culprits. Moreover, the role of left atrial and annular dynamics in provoking MR is often underappreciated. Because of this peculiar pathophysiology, atrial functional MR benefits from a different approach compared with secondary MR. Although both AF and HFpEF—two closely related disease epidemics of the 21st century—are held responsible, current guidelines do not emphasize the need to differentiate atrial functional MR from (ventricular) secondary MR. This review summarizes the prevalence and prognostic importance of atrial functional MR, providing mechanistic insights compared with those of secondary MR and suggesting potential therapeutic targets.